Is Johnson & Johnson (JNJ) Undervalued?
The traditional Graham Number cannot be calculated for Johnson & Johnson (JNJ) due to missing data. Consider using DCF or other valuation methods for a complete picture.
Analysis updated March 6, 2026
JNJ Key Valuation Metrics
| Metric | Value | Signal |
|---|---|---|
| Current Price | $239.89 | — |
| Graham Number | N/A | — |
| P/E Ratio | N/A | Unprofitable |
| P/B Ratio | 7.14 | ▼ High |
| DCF Fair Value | N/A | — |
| Dividend Yield | 2.17% | — Moderate |
| 52-Week Range | $141.50 – $251.71 | Near 52-week high |
| Market Cap | N/A | Micro Cap |
| Sector | Healthcare | — |
How We Calculated JNJ's Graham Number
The Graham Number, developed by Benjamin Graham (the father of value investing), estimates a stock's maximum fair price based on its earnings and book value.
Graham Number = √(22.5 × EPS × BVPS)
For Johnson & Johnson (JNJ):
- Earnings Per Share (EPS): N/A
- Book Value Per Share (BVPS): N/A
JNJ Dividend Profile
Johnson & Johnson currently pays a quarterly dividend of $1.30 per share, yielding 2.17% at the current price.
| Annual Dividend | $5.20 |
| Dividend Yield | 2.17% |
| Payout Ratio | N/A |
| Consecutive Years Paid | 5+ years |
| 5-Year Dividend Growth | -26.5% |
| Payment Frequency | Quarterly |
👑 Johnson & Johnson is a Dividend Aristocrat — it has increased its dividend for 25+ consecutive years.
Dividend History
JNJ Value Score: 2/10
Our proprietary value score rates Johnson & Johnson a 2 out of 10, placing it in the “Overvalued / Caution” category for value investors.
Score Components
Graham Number not available
P/E not available
Significant premium to book value
DCF value not available
Solid 2.2% yield
Adequate financial health
Score methodology: How We Score Stocks
Stocks Similar to JNJ
These Healthcare stocks have similar valuation profiles to Johnson & Johnson:
Frequently Asked Questions About JNJ
Is JNJ undervalued right now?
Based on Graham Number analysis, JNJ does not appear significantly undervalued as of March 6, 2026. The Graham Number of $N/A compared to the current price of $239.89 indicates a N/A% difference.
What is Johnson & Johnson's intrinsic value?
Using our DCF model, Johnson & Johnson's estimated intrinsic value is $N/A per share. The Graham Number suggests a fair value of $N/A.
What is the Graham Number for JNJ?
The Graham Number for JNJ is $N/A, calculated using EPS of $N/A and Book Value Per Share of $N/A. The formula is sqrt(22.5 x EPS x BVPS).
Does JNJ pay a dividend?
Yes, JNJ pays dividends with a yield of 2.17%. The annual dividend is $5.20 per share. It has paid dividends for 5+ consecutive years.
Is JNJ a good buy right now?
Our value score rates JNJ a 2/10. The stock is in the "Overvalued / Caution" category. However, this is analysis — not financial advice. Consider your own risk tolerance, portfolio allocation, and investment timeline before making any decisions.
Start Analyzing JNJ Today
Ready to invest in Johnson & Johnson? Open a free brokerage account and start trading JNJ with $0 commissions.
We may earn a commission when you open an account through our links. This does not affect our analysis or ratings.
Learn More About Value Investing
Tools
- Graham Number Calculator — Calculate the Graham Number for any stock
- DCF Calculator — Run your own discounted cash flow analysis
- Stock Screener — Filter stocks by value metrics
Related Articles
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment...
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice, a recommendation, or a solicitation to buy or sell any security. Past performance does not guarantee future results. Always do your own research and consult a licensed financial advisor before making investment decisions. Data sourced from Financial Modeling Prep API and may be delayed. Last updated: March 6, 2026.